Cat. No.
MABL-925
Application
ELISA, FC, Inhibit,
Isotype
Engineer antibody
Species Reactivity
chimpanzee, Human, Cynomolgus Monkey
Clone No.
6G5 (Zanolimumab)
From
Recombinant Antibody
Specificity
This antibody binds human CD4.
Alternative Names
Lu/T4; T-cell surface glycoprotein CD4; T-cell surface antigen T4/Leu-3
UniProt
P01730
Immunogen
The original antibody was generated by immunizing transgenic mice having functionally disrupted endogenous heavy chain loci (J.sub.HD) and harboring a human heavy chain minigene construct (HC1) with human blood from a single donor.
Application Notes
Zanolimumab (clone 6G5, HuMax-CD4, MDX CD4, MDX-016) was among the first fully human mAbs generated from human Ig transgenic mice. The antigen specificity of this antibody was determined using ELISA (PMID: 9631008). The mAb 6G5 was subsequently re-expressed in CHO cells without altering its binding or functional characteristics and renamed HM6G. The avidity of 6G5 for native CD4 expressed on human and nonhuman primate lymphocytes was examined in a flow cytometry assay (PMID: 10444358). Zanolimumab inhibitsCD4+T cells by combining signaling inhibition with potent induction of Fc-mediated effector functions. T cell activation is inhibited by a fast dual mechanism in which the antibody abrogates signaling via the T cell receptor (TCR) and, in addition, down regulates T cell activation by transmission of direct inhibitory signals. In addition, zanolimumab induces killing of CD4+ T cells via antibody-dependent cellular cytotoxicity (PMID: 17942927). Zanolimumab exhibits cytotoxic and anti-proliferative effects and has shown efficacy in T-cell lymphomas. A clinical efficacy and safety study of treatment with weekly dose of 980 mg of HuMax-CD4 in 8 patients having refractory or relapsed CD4+ peripheral T-cell lymphoma (PTCL) of non-cutaneous type revealed that Zanolimumab is well tolerated (PMID: 20629661). Zanolimumab has also been reported to cause depletion of CD4+ T cells from human skin in a human psoriasis xenograft mouse model (PMID: 17091277).
Antibody First Published
Fishwild et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol. (1996); 14(7):845-51. PMID:9631008
Note on publication
Describes the generation of humanized antibodies using transgenic mice.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
